samuraciclib in combination with fulvestrant in patients with advanced hr /her2- breast cancer
Published 2 years ago • 354 plays • Length 5:02Download video MP4
Download video MP3
Similar videos
-
1:41
postmonarch: abemaciclib with fulvestrant in pretreated hr /her2- breast cancer
-
1:02
phase iii trial of pf-07220060 and fulvestrant in hr /her2- breast cancer
-
5:12
monarch 2: abemaciclib added to fulvestrant shows os benefit in hr /her2- advanced breast cancer
-
2:02
palbociclib combined with fulvestrant in relapsed metastatic hr /her2- breast cancer
-
1:49
phase ib data capitello-292: capivasertib palbociclib fulvestrant in hr /her2- breast cancer
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
0:53
postmonarche: abemaciclib fulvestrant in hr /her2- mbc following cdk4/6i & endocrine therapy
-
10:15
monaleesa-3 os results: fulvestrant/ribociclib in postmenopausal hr /her2- advanced breast cancer
-
4:06
serena-2: camizestrant vs fulvestrant in post-menopausal women with advanced er /her- breast cancer
-
3:09
overall survival results from monaleesa-3 study on ribociclib plus fulvestrant in advanced breas...
-
1:39
frontline endocrine therapies and ribociclib in early stage hr her2- breast cancer
-
5:28
capitello-291: capivasertib fulvestrant for ai-resistant hr /her2- advanced breast cancer
-
5:00
penelope-b: palbociclib with endocrine therapy in hr , her2-negative breast cancer
-
1:18
the significance of fulvestrant for hormone receptor-positive advanced breast cancer
-
1:21
qol in monaleesa-2, 3, and 7
-
15:13
gs3-10: "study of samuraciclib (ct7001), a first-in-class, oral, selective inhibitor of cdk7, in.."
-
0:54
treatment de-escalation in premenopausal patients with hr /her2- breast cancer and micro-metastasis
-
4:29
pertuzumab, trastuzumab and cyclophosphamide in older patients with her2 breast cancer
-
2:10
monarche: adjuvant abemaciclib endocrine therapy in patients with hr , her2- high-risk ebc